Results 61 to 70 of about 6,043 (288)

Galcanezumab-induced fixed drug eruption

JAAD Case Reports, 2021
Skylar Klager, SM, Marina Khalil, BS, Kenneth Shulman, MD, Naveed Sami, MD   +3 more
doaj   +1 more source

Broadening the View: Substance P and Its Metabolism in Pruritus‐Related Diseases

The Journal of Dermatology, EarlyView.
ABSTRACT Chronic pruritus is a debilitating symptom accompanying numerous inflammatory skin diseases and remains a major therapeutic challenge. Neurogenic inflammation plays a central role in its pathogenesis, with the tachykinin substance P acting as a key mediator at the interface of the nervous system, immune cells, and cutaneous tissues.
Thomas Walter, Bjoern B. Burckhardt
wiley   +1 more source

Fixed Eruptions: Drug, food, and what more?

Clinical Dermatology Review
Fixed drug eruption (FDE) is a common entity encountered in our day-to-day clinical practice. It is a T-cell-dependent pathway with induction of interferon-gamma-producing CD8+ T-cells in the dermis and epidermis.
Prabhakar Mallikarjuna Sangolli, Neethu Mary George   +1 more
doaj   +1 more source

AN URBAN MARKETPLACE UNDER PRESSURE: The Steady Gentrification Process of Porta Palazzo (Turin) Through the Eyes of Market Sellers and Policy Makers

International Journal of Urban and Regional Research, EarlyView.
Abstract Marketplaces, crucial sites for low‐income populations as sources of affordable goods and social interaction, are at a critical juncture. They are experiencing decline due to the rise of shopping centres and neglect by public authorities, while at the same time being rediscovered as tourist attractions, sources of profit and tools for urban ...
Francesca Ru
wiley   +1 more source

Recurrent fixed drug eruption caused by citiolone

, 1997
Citiolone (N-acetylhomocysteinethiolactone) is a thiolic­derived medication frequently used in Spain and in other countries as a mucolytic agent for the treatment of certain hepatic disorders. Mucolytic drugs have rarely been implicated in the fixed drug
Barrio, Manuel de, Tornero Molina, Pilar, Sainza, T., Zubeldia Ortuño, José Manuel, Prieto, A., Herrero, T.   +5 more
core  

Generalized fixed drug eruption to piperacillin/tazobactam and review of literature [PDF]

, 2018
Fixed drug eruption (FDE) is an adverse drug reaction characterized by the development of well-circumscribed, round, dusky erythematous macules and plaques on cutaneous or mucosal surfaces.
Konia, Thomas, Fung, Maxwell A, Tartar, Danielle M, Gorouhi, Farzam, Kornmehl, Heather   +4 more
core   +1 more source

Interactional privilege of violence: Status and interaction in the street field

Criminology, EarlyView.
Abstract Criminologists have long described and theorized the relationship between status, respect, and violence within urban communities. Although this finding is generally accepted within criminology, ethnographic empirical illustrations of this phenomenon are sparse.
Hakan Kalkan, Heith Copes
wiley   +1 more source

Management of Treatment Resistant EGFR Inhibitor‐Induced Papulopustular Exanthema With Isotretinoin and Dapsone

Australasian Journal of Dermatology, EarlyView.
ABSTRACT Background/Objectives Epidermal growth factor receptor inhibitors (EGFRi) commonly cause papulopustular exanthemas that may compromise the success of cancer therapy. While tetracyclines are first‐line treatment, data on alternative systemic agents for refractory cases remain limited.
Ishana Dixit, Raquel Ruiz Araujo, Pablo Fernandez‐Peñas   +2 more
wiley   +1 more source

The Harmful Trifecta of Skincare in African and Asian Populations: Triple Action Creams, Skin‐Lightening Creams, and Antiseptic Soaps

JEADV Clinical Practice, EarlyView.
Olufolakemi Cole‐Adeife, Monisha Madhumita, Doreen Mapunda, Daudi Mavura, Fatimata Ly   +4 more
wiley   +1 more source

Dupilumab's Real‐World Efficacy and Safety Across Age Groups for Children and Adolescents With Paediatric Atopic Dermatitis

Australasian Journal of Dermatology, EarlyView.
ABSTRACT Background/Objectives Dupilumab is an anti‐interleukin (IL)‐4 receptor (IL‐4Rα) monoclonal antibody used to manage atopic dermatitis (AD). There is a paucity of real‐world Australian data for dupilumab in paediatric AD, especially regarding differences in clinical profiles between age groups.
Paul Sun Woo Kim, Jacqueline Tu, Kelvin Truong, Gloria Fong, William Luu, Peter Barclay, Melanie Wong, Li‐Chuen Wong   +7 more
wiley   +1 more source